Galena Biopharma this week said that it has taken steps to end a dispute with investors that threatened to block the company's planned spinout of RNAi subsidiary RXi Pharmaceuticals.

As reported by Gene Silencing News, Galena was sued by a handful of investment firms alleging that protections within securities-purchase agreements they struck with the company require the biopharmaceutical company to buy back millions in devalued warrants.

The lawsuits sought a combined $5.2 million from Galena.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.